CIK 0001649989
- Non-accelerated filer
- Smaller reporting company
Outlook Therapeutics, Inc.
Sign in to watch- Ticker
- OTLK
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Sep 30
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 383982704
- Phone
- +1 609-619-3990
- Business address
- 111 S. WOOD AVENUE, UNIT #100, ISELIN, NJ, 08830
- Former names
- Oncobiologics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 71 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-03-19 | Sukhtian Faisal Ghiath Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2020-03-19 | HILZINGER KURT J Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2020-03-19 | Haddadin Yezan Munther Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2020-03-19 | THURMAN RANDY H Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2020-02-26 | Sukhtian Ghiath M. Director | Grant or award | +2,460,630 | $1.02 | $2.5M | 2,460,630 |
| 2020-02-26 | Sukhtian Ghiath M. Director | Grant or award · Warrants | +1,230,315 | $0.13 | $154K | 1,230,315 |
| 2020-01-29 | BioLexis Pte Ltd. Director | Option exercise | +4,657,852 | $0.23 | $1.1M | 21,606,437 |
| 2020-01-29 | BioLexis Pte Ltd. Director | Option exercise · Warrant (Right to Buy) | −2,093,750 | 0 | ||
| 2020-01-29 | BioLexis Pte Ltd. Director | Option exercise · Warrant (Right to Buy) | −1,282,051 | $1.00 | $1.3M | 0 |
| 2020-01-29 | BioLexis Pte Ltd. Director | Option exercise · Warrant (Right to Buy) | −1,282,051 | $1.00 | $1.3M | 0 |
| 2020-01-27 | BioLexis Pte Ltd. Director | Returned to the company · Warrant (Right to Buy) | −2,093,750 | 0 | ||
| 2020-01-27 | BioLexis Pte Ltd. Director | Grant or award · Warrant (Right to Buy) | +2,093,750 | 2,039,750 | ||
| 2020-01-27 | BioLexis Pte Ltd. Director | Returned to the company · Warrant (Right to Buy) | −1,282,051 | $1.00 | $1.3M | 0 |
| 2020-01-27 | BioLexis Pte Ltd. Director | Grant or award · Warrant (Right to Buy) | +1,282,051 | $1.00 | $1.3M | 1,282,051 |
| 2020-01-27 | BioLexis Pte Ltd. Director | Returned to the company · Warrant (Right to Buy) | −1,282,051 | $1.00 | $1.3M | 0 |
| 2020-01-27 | BioLexis Pte Ltd. Director | Grant or award · Warrant (Right to Buy) | +1,282,051 | $1.00 | $1.3M | 1,282,051 |
| 2020-01-02 | Haddadin Yezan Munther Director | Grant or award · Stock Option (Right to Buy) | +5,980 | $0.99 | $6K | 5,980 |
| 2019-12-31 | BioLexis Pte Ltd. Director | Other acquisition · Series A-1 Convertible Preferred Stock | +1,661 | 68,112 | ||
| 2019-12-23 | BioLexis Pte Ltd. Director | Option exercise | +2,909,091 | $0.23 | $675K | 16,948,585 |
| 2019-12-23 | BioLexis Pte Ltd. Director | Option exercise · Warrant (Right to Buy) | −3,636,364 | 0 |
Page 12 of 14 · 276 trades